Product image of Norifaz (Risedronate Sodium) supplied by GNH India

Norifaz

Active Ingredient:
Risedronate Sodium
Origin:
EU

Norifaz (Risedronate Sodium)

Risedronate Sodium, the active ingredient in Norifaz, is a bisphosphonate presented as an oral dosage form for oral use. It treats osteoporosis and related bone disorders in postmenopausal women and patients receiving glucocorticoids.

GNH India supplies Norifaz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zakład Farmaceutyczny Adamed Pharma Spółka Akcyjna

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Risedronate Sodium is used to manage bone‑resorptive disorders within the osteoporosis therapeutic area.

  • Postmenopausal osteoporosis: improves bone mineral density and reduces fracture risk.
  • Glucocorticoid‑induced osteoporosis: helps maintain bone strength in patients on long‑term steroids.
  • Paget's disease of bone: normalizes abnormal bone remodeling and alleviates disease symptoms.

How It Works

  • Risedronate Sodium binds selectively to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the bone surface, the drug is internalized and inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. This disruption impairs osteoclast function and induces apoptosis, thereby reducing bone resorption and allowing bone formation to predominate, which increases overall bone mineral density.

Side Effects

Risedronate Sodium may cause a range of adverse reactions, from mild to serious. Patients should be aware of the most frequently reported events as well as rarer but potentially severe outcomes.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
  • Musculoskeletal pain: transient bone, joint, or muscle aches.
  • Headache: mild to moderate intensity.
  • Esophageal irritation: especially when tablets are not taken with sufficient water.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: persistent exposed bone in the oral cavity.
  • Atypical femoral fractures: low‑energy fractures of the subtrochanteric region.
  • Severe hypersensitivity: rash, angioedema, or anaphylactic reactions.

Precautions & Warnings

Before initiating therapy with Risedronate Sodium, several safety considerations should be observed.

  • Renal function: assess kidney function and avoid use in severe renal impairment.
  • Gastrointestinal disorders: evaluate history of esophageal disease or ulcers before prescribing.
  • Calcium/vitamin D status: ensure adequate supplementation to support bone health.
  • Concomitant medications: review for drugs that may increase risk of hypocalcemia.
  • Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Avoid Interactions

Risedronate Sodium can interact with several medicines, altering its absorption or increasing adverse effect risk.

Major Interactions (Avoid)

  • Calcium supplements or antacids containing aluminum/magnesium: reduce drug absorption; separate dosing by at least 2 hours.
  • Oral bisphosphonates taken concurrently: may increase cumulative toxicity.
  • Concomitant use with high-dose corticosteroids: heighten risk of gastrointestinal irritation.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of upper GI ulceration.
  • Proton pump inhibitors: may affect drug dissolution and absorption.
  • Diuretics: monitor serum calcium levels for potential hypocalcemia.

Frequently Asked Questions

Norifaz contains risedronate sodium, a bisphosphonate indicated for postmenopausal osteoporosis, glucocorticoid‑induced osteoporosis, and Paget's disease of bone. In these conditions it helps increase bone mineral density and lowers the risk of fractures by inhibiting bone resorption.

Risedronate sodium binds to bone mineral at sites of active remodeling. When osteoclasts attach to the bone surface, the drug is taken up and blocks farnesyl pyrophosphate synthase, an enzyme essential for osteoclast function. This leads to reduced bone resorption and a net gain in bone density.

The specific dose of Norifaz is determined by the prescribing clinician based on the patient’s condition, renal function, and other individual factors. Healthcare professionals follow local prescribing guidelines to select the appropriate regimen.

Safety data for risedronate sodium in pregnancy and lactation are limited. It is generally avoided unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Norifaz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Norifaz (risedronate) belongs to the bisphosphonate class, which directly inhibits osteoclast‑mediated bone resorption. Compared with other oral bisphosphonates such as alendronate, risedronate offers similar efficacy in increasing bone density but may have different dosing schedules and tolerability profiles. It is distinct from newer agents like denosumab, which act via RANKL inhibition.

Norifaz should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability.

Norifaz is taken orally, usually as a tablet. The tablet should be swallowed with a full glass of plain water on an empty stomach, at least 30 minutes before the first food, beverage, or other medication of the day. Patients should remain upright for at least 30 minutes after dosing to reduce esophageal irritation.

The most serious adverse events linked to risedronate include osteonecrosis of the jaw, atypical femoral fractures, and severe hypersensitivity reactions such as anaphylaxis. Patients should report persistent jaw pain, unusual thigh or groin pain, or any signs of allergic reaction to their healthcare provider promptly.

Norifaz is contraindicated in patients with known hypersensitivity to risedronate or other bisphosphonates, severe renal impairment (creatinine clearance <30 mL/min), and those with esophageal abnormalities that delay emptying. Caution is also advised for individuals with low calcium levels or active dental problems.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Risedronate Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT